Nasdaq: SUPN

Supernus Pharmaceuticals, Inc. (SUPN)

Supernus Pharmaceuticals, Inc. is a public company that reports to the U.S. Securities and Exchange Commission and trades on Nasdaq under the ticker SUPN. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.

Key facts

Ticker symbol
SUPN
Exchange
Nasdaq
SEC CIK
1356576
Official filings
SEC EDGAR

Research SUPN

  • Profile — Business description, headquarters, subsidiaries and corporate identifiers.
  • Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
  • SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
  • Stock Analysis — Price chart, returns, technical indicators and related companies.
  • News — Latest headlines and press coverage.
  • Material Contracts — Material agreements filed as exhibits to SEC reports.
  • Benchmark — Stock performance against the S&P 500, Nasdaq-100 and Dow (through SPY, QQQ and DIA) and economic indicators.
  • Peer Comparison — Side-by-side financial ratios against industry peers.

Frequently asked questions

What is Supernus Pharmaceuticals, Inc.'s stock ticker?

Supernus Pharmaceuticals, Inc. trades under the ticker symbol SUPN on Nasdaq. Its SEC Central Index Key (CIK) is 1356576.

Where can I read Supernus Pharmaceuticals, Inc.'s SEC filings?

The SUPN SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Supernus Pharmaceuticals, Inc. has filed, with AI analysis. The original documents are also on SEC EDGAR.

How can I analyze SUPN's financial statements?

The SUPN Financials page shows Supernus Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.

How does SUPN compare with its peers and the market?

The SUPN Peer Comparison page lines Supernus Pharmaceuticals, Inc. up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500, the Nasdaq-100 and the Dow.

For information only — not investment advice.